跳至主要内容
临床试验/ISRCTN13681882
ISRCTN13681882已完成未知

Short term recombinant human Growth Hormone administration increases strength and power, but does it improve sporting performance in anabolic-androgenic steroid users?

niversity of Glamorgan0 个研究点目标入组 48 人开始时间: 2006年10月27日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Healthy individual weight lifters, who were previous experienced users of AAS, in a 12 week abstinent phase

排除标准

  • Positive urinalysis for ergogenic aids

研究者

发起方
niversity of Glamorgan

相似试验

进行中(未招募)
不适用
Treatment With Recombinant Human Growth Hormone (Genotonorm) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and SafetyJuvenile idiopathic arthritis (JIA) and nephrotic syndrome (NeS)
EUCTR2014-004104-30-Outside-EU/EEAPharmacia & Upjohn S.A.30
进行中(未招募)
1 期
Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis - rhGH in MSMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10063400Term: Secondary progressive multiple sclerosisMultiple Sclerosis
EUCTR2006-006465-16-DEniversity of Leipzig
已完成
Unknown
Administration study of long-acting growth hormone preparations in healthy adultsHealty adult subjectsSample collection for evaluating analysis and sampling methods in antidoping
JPRN-jRCT1001220001Yonemura Takuma12
进行中(未招募)
1 期
Treatment with recombinant Growth Hormone in Children born Small for Gestational Age (SGA) without Catch-up Growth. - Not applicableShort stature in children born small for gestational age without catch up growth
EUCTR2005-001507-19-IEational Children's Hospital & Trinity College Dublin350
进行中(未招募)
不适用
Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GHSpinal muscular atrophy (SMA) is an autosomal recessive disease. Due to the genetic defect, a molecule called spinal motor neuron” (SMN) protein is lacking, resulting in muscle weakness. In SMAs muscle weakness is found most often at the level of proximal muscles. The disease is life-threatening and chronically debilitating.
EUCTR2005-002822-78-DEKlinik Neuropädiatrie und Muskelkrankheiten20